A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis

Phase 2

Completed

• Conditions: Cystic Fibrosis

• Registration Number: NCT00455130
• Lead Sponsor: Syntara

Brief Summary

Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung infection with emphysema), sweat glands and reproductive organs. We know that many CF patients die of lung failure, brought about in part by repeated lung infections caused by thick, sticky mucus that cannot be readily cleared from the lung.

Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies that have examined mucociliary clearance, quality of life and lung function in CF and bronchiectasis. The promising results of these studies warrant futher investigation. The aim of this study is to assess the safety and efficacy of inhaled mannitol when administered twice a day over two weeks in CF.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03
• Study Completion: 2005-08
• Study First Submitted: 2007-04-02
• Study First Submitted QC: 2007-04-02
• Study First Posted: 2007-04-03
• Status Verified: 2010-01
• Last Update Submitted: 2010-01-31
• Last Update Posted: 2010-02-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Confirmed diagnosis of cystic fibrosis (sweat test/genotype)

2. Aged 8 years or older

3. Have FEV1 between 40% and 80% of predicted for height, age and gender OR a decrease in FEV1 of 20% or more than that recorded 6-12 months previously.

4. As determined by the investigator, are capable and willing to

   • Use the study diary as required for this protocol
   • Able to perform all of the techniques necessary to measure lung function
   • Able to administer the dry powder mannitol

5. Are capable of and have given informed consent

6. Clinically stable at study entry

Exclusion Criteria

1. Investigators, site personnel directly affiliated with this study, and their immediate families.
2. Subjects under the age of 8 years.
3. Subjects with currently active asthma
4. Subjects using hypertonic saline treatment in the last 2 weeks
5. Considered "terminally ill" or listed for transplantation
6. Requiring home oxygen or assisted ventilation
7. Colonisation with Burkholderia cepacia
8. Significant episode of hemoptysis (>60 mls) in the previous 12 months
9. Myocardial Infarction in the six months prior to enrolment.
10. Cerebral Vascular Accident in the six months prior to enrolment.
11. Ocular surgery in the three months prior to enrolment.
12. Abdominal surgery in the three months prior to enrolment.
13. Subjects who are breast feeding or pregnant.
14. Female subjects of reproductive capability, not using a reliable form of contraception
15. Inability to obtain informed consent from the subject or subject's authorised representative.
16. Subjects who have participated in another investigative drug study parallel to, or within 4 weeks of study entry.
17. Known intolerance to mannitol or beta2 agonists.
18. Uncontrolled hypertension - systolic BP > 160 and or diastoli

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
FEV1

Secondary Outcome Measures

Name	Time	Method
Other measures of lung function
Quality of life
Sputum microbiology
Sputum rheology
Safety

Trial Locations

Locations (8)

Royal Children's Hospital; 🇦🇺 Melbourne, Victoria, Australia

The Alfred Hospital; 🇦🇺 Melbourne, Victoria, Australia

Princess Margaret Hospital for Children; 🇦🇺 Perth, Western Australia, Australia

Sir Charles Gairdner; 🇦🇺 Perth, Western Australia, Australia

Royal Prince Alfred Hospital; 🇦🇺 Sydney, New South Wales, Australia

Childrens Hospital at Westmead; 🇦🇺 Sydney, New South Wales, Australia

Greenlane Hospital; 🇳🇿 Auckland, North Island, New Zealand

Prince Charles Hospital; 🇦🇺 Brisbane, Queensland, Australia